The aim of this study is to evaluate clinical benefits of recombinant adenoviral human p53 (rAd-p53) gene therapy combined with radiotherapy in prevention of oral cancer recurrence after a radical resection. A total of 51 patients with tongue cancer (TCa) and 56 patients with gingival carcinoma (GCa) satisfying the inclusion criteria were randomly assigned to two groups: the experiment group (EG) and the control group (CG). The EG group received multipoint injections of rAd-p53 into the surgical wound surface at a dose of 1 Â 10 12 viral particles after a radical resection. Patients in both EG and CG were given radiotherapy at a total dose of 60 Gy at 3 weeks after surgery. All these patients were followed up for at least 3 years. Two cases (2/27) of TCa and 2 (2/30) in GCa patients had a local recurrence in EG, but 8 (8/24) TCa and 8 (8/26) GCa patients in CG had a local recurrence. Both recurrent rates of TCa (33.3%) and GCa (30.8%) in CG are statistically significantly higher than those of TCa (7.4%) and GCa (6.7%) in EG, respectively. The overall recurrent rate in EG is 7%, which is also statistically significantly lower than that (32%) in CG. The 3-year overall survival (OS) rate and 3-year disease-free survival (DFS) rate of EG is 100% and 93%, respectively. The 3-year OS and DFS rates of CG are 94 and 68%, respectively. Mild or medium fever and flu-like symptoms were more frequently observed in EG and were considered to be associated with application of rAd-p53. Post-tumorectomy wound surface injection of rAd-p53 combining with radiotherapy is a safe and effective regimen for the patients with TGa or GCa.
INTRODUCTION
The p53 gene has been well characterized and is one of most important tumor suppressor genes. It has multiple antitumor functions, including blocking cell cycle, inducing cell apoptosis, inhibiting tumor angiogenesis and sensitizing tumor to chemotherapy and radiotherapy. p53 mutation occurs in up to 63% of oral squamous carcinoma. 1, 2 Loss of normal functions of p53 is associated with tumorigenesis, chemotherapy and radiotherapy resistance. 3, 4 Gendicine is the brand name of recombinant adenoviral human p53 gene (rAd-p53), in which, a wild-type p53 gene was inserted into a replication-defective type-V adenovirus. A phase II clinical trial of the rAd-p53 gene therapy plus radiotherapy compared with radiotherapy alone in treatment of patients with advanced head and neck cancer showed that the combined therapy significantly improved the 5-year overall survival (OS) and progression-free survival. 5 Several reports demonstrated that rAd-p53 was effective for advanced lung, liver, breast and cervical cancers. [6] [7] [8] [9] [10] Surgery is a mainstay of treatment for oral cancer. Radiotherapy with or without systemic chemotherapy is usually used for an adjuvant to surgery, or for cases unable to tolerate or unsuited for surgery, or as a salvage treatment. 11 The tumor stage, size, location and patient's general condition are factors that influence treatment options. Although progress has been made in treatment of oral squamous carcinoma, the 5-year OS rate is still kept around 50%. 12 Local recurrence is a main reason of treatment failure. [13] [14] [15] [16] On the basis of favorable safety profile and synergistic antitumor effect with radiotherapy of rAd-p53, [5] [6] [7] [8] [9] [10] we hypothesize that post-surgery p53 gene therapy combined with radiotherapy can further reduce local recurrence and improve survival in oral cancer.
MATERIALS AND METHODS
The study was approved by the hospital ethics committee (Ethics Committee, 301 Military General Hospital, Beijing 100853, China), but was not registered in an international clinical trial registry platform. All the enrolled patients signed a consent form.
Patients
From January 2005 to April 2011, a total of 107 patients with tongue cancer (TCa) or gingival carcinoma (GCa) satisfying the inclusion criteria were randomly assigned to two groups: the experiment group (EG) and the control group (CG). The EG group included 57 patients, 27 of them with TCa and 30 with GCa, and the CG group included 50 patients, 24 with TCa and 26 with GCa. The randomization schedule was generated using the SAS PROC PLAN procedure (SAS Institute, Cary, NC, USA). The inclusion criteria are as follows: histopathologically diagnosed TCa or GCa; those carcinomas that were considered as resectable; patients over 18 years old; those with an Eastern Cooperative Oncology Group score of 0-2; those with normal hemogram, blood coagulation, liver and kidney function tests; those who understood and signed the informed consent form. The patients' characteristics and disease stage are summarized in Table 1 by the treatment group. The sixth edition of the tumor node metastasisstaging system for head and neck is used for staging tumors.
Treatments rAd-p53 (brand name is Gendicine) was purchased from Shenzhen SiBiono Gene Tech (Shenzhen, China). Patients in the EG group received surgical wound surface injection of rAd-p53 at a dose of 1 Â 10 12 viral particles after a radical resection of tumor and radiotherapy at 3 weeks after the surgery. rAd-p53 was diluted into 5 ml of physiological saline and then was injected into the surgical wound surface at multiple points to cover all the surgical margins. Patients in the CG group received radiotherapy alone at 3 weeks after surgery, at the same dosage as that used for those in the EG group. Radiotherapy was given five times a week for 6 weeks, for a total dose of 60 Gys. All these patients were followed up every 3 months. Routine physical examination, lab tests, including hemogram, liver and kidney function tests, and morphologic imaging tests were performed during each follow-up.
Study design and statistical methods
This is a randomized, controlled and unmasked phase II study. The primary study end point is the local recurrent rate. The secondary study end points are 3-year disease-free survival (DFS) and OS, and the safety parameters of rAd-p53. The local recurrence was determined by computerized tomography or magnetic resonance imaging. DFS is defined as the period from date of surgery up to date of first detected recurrence, locoregional or systemic.Death caused by tumor progression was the event of OS. The safety profile of rAd-p53 was determined by assessing adverse events, physical examinations and lab tests. This is an exploratory study. The sample size was not determined based on a hypothesis test. A total of 110 patients with TCa or GCa were recruited and randomly assigned to the EG and CG groups with a 1:1 ratio. The randomization schedule was generated using the SAS PROC PLAN procedure, and two treatments were randomly assigned to the patients' sequential ID number without stratification based on stage.
The local recurrent rates of the two groups are compared using Fisher's exact test. The DFS and OS were estimated using the Kaplan-Meier method, and the log-rank test was used to compare DFS and OS between the two treatment groups. Statistical significant level was 0.05 (type I error, a ¼ 0.05). SAS9.2 was used for statistical analyses.
RESULTS
A total of 107 patients were recruited. All these patients had finished the 3 years follow-up. Two (2/27) TCa and 2 (2/30) GCa patients in EG had a local recurrence, but 8 (8/24) TCa and 8 (8/26) GCa patients in CG had a local recurrence. Both recurrent rates of TCa (33.3%) and GCa (30.8%) in CG are statistically significantly higher than that of TCa (7.4%) and GCa (6.7%) in EG, respectively. The overall recurrent rate in EG is 7.0%, which is also statistically significantly lower than that (32%) in CG. Table 2 presents summaries and comparisons of recurrences in the two groups. Figure 1 shows the recurrent rates of TCa and GCa in EG and CG groups, respectively.
Three-year OS rates of EG and CG groups were 100% and 94%, respectively. All the patients in EG were alive at the 3-year visit. Three patients in CG died from tumor progression at 26, 29 and 32 month, respectively. The difference in OS between the two groups was not statistically significant (log-rank test: P-value ¼ 0.0586). Figure 2 presents the OS curves of the two groups. Three-year DFS rates of EG and CG were 93% and 68%, respectively. The median survival time could not be estimated, because most patients in the study were alive at the end of the study. The difference in DFS between the two groups was statistically significant (log-rank test: P-value ¼ 0.0002). Figure 3 presents the DFS curves of the two groups.
Adverse events are graded according to Common Terminology Criteria for Adverse Events (version 4.03). Fever and flu-like symptoms were more frequently observed in the EG group. Post-surgery radiotherapy and rAd-p53 therapy S Liu et al Forty-eight patients (84.2%) in EG had fever of 37.5-39.2 1C versus 12% of the patients in CG with fever of 37.5-38 1C. The fever lasted 2-12 h and reduced to normal without any treatment, or by physical cooling. The observed adverse events considered being related to radiotherapy included oral membrane dryness, burn or pain. Table 3 summarizes the adverse events with the Common Terminology Criteria for Adverse Events grade by treatment.
DISCUSSION
Wild-type p53 gene has an important role in the regulation of cell cycle and apoptosis, and suppresses tumor growth. 18 Normal and functional p53 protein is associated with preventing tumorigenesis, inhibiting tumor growth and metastasis, increasing tumor sensitivity to radiotherapy and chemotherapy. 19, 20 The mutant forms of the p53 protein have lost these tumor suppressor activities. Some mutant forms of p53 may gain new reversal functions and interfere with the antitumor effects of wild-type p53. Previous studies showed that the introduction of wild-type p53 gene into tumor cells recovered the antitumor activities of p53 and also regain tumor sensitivity to chemotherapy and radiotherapy. [21] [22] [23] Preclinical data show marked anticancer effects of the p53 gene. 24 Viral-based vectors demonstrated a high level of both transfection and expression of the gene. 24 p53 gene delivered using an adenoviral or retrovirus viral vector has been demonstrated to be effective and safe in treatment of several types of malignant tumors. [25] [26] [27] [28] [29] As early as the middle and late 1990s, intratumoral injection of adenoviral or retroviral p53 expression vector for treating lung and head and neck cancer had been investigated in the United States. [25] [26] [27] [28] [29] These studies showed an improvement of local tumor control and a favorable safety profile of adenoviral or retroviral p53 expression vector. In 2004, rAd-p53 was approved by China's State Drug and Food Administration for the treatment of head and neck cancer. A phase II clinical trial using rAd-p53 intratumor injection combined with radiotherapy in treatment of patients with advanced head and neck cancer showed that the p53 gene therapy combined with radiotherapy significantly increased complete response rate, overall response rate, the 5-year OS and progression-free survival rates, and prolonged OS and progression-free survival when compared with radiotherapy alone. 5 Several reports demonstrated that rAd-p53 is effective for the lung, liver, breast and cervical cancers, and some precancerous lesions, such as oral leukoplakia and cervical displasia. In these clinical studies, the p53 gene therapy was combined with chemotherapy, radiotherapy, or chemo-and radiotherapy. In the treatment of liver cancer, the gene therapy was often used with transcatheter arterial chemoembolization. The p53 gene therapy was also used in combination with surgery: before, during or after a surgery. The surgical wound injection of rAd-p53 has been used for preventing local recurrence of malignant gliomas, colon and rectal cancer, and cervical cancer (unpublished data). So far, there has been no sufficient data to prove the long-term efficacy yet. Therefore, we conduct this study to find the effectiveness of surgical wound injection of rAd-p53 in preventing local recurrence of oral tumor after a radical resection.
Depending on the primary tumor site and stage of disease, patients with oral squamous cell carcinomas develop locoregional recurrence in 30-50% of cases. 12 The residual tumor cells or premalignant cells in a resection margin are believed to be a highrisk factor for local recurrence. Wide local excision and high-dose radiotherapy were standard methods for preventing local recurrence, but the sequelae of those methods are substantial morphological and functional damage. In this study we used the surgical-wound-surface injection of rAd-p53 combined with radiotherapy to prevent local recurrence after a radical tumorectomy. The data presented in this report indicated a trend that this treatment regimen did decrease the local recurrent rate and also improved OS and DFS. This study also shows rAd-p53 was safe and well tolerated. Mild or medium fever and flu-like Post-surgery radiotherapy and rAd-p53 therapy S Liu et al symptoms are more frequently observed in EG and considered to be associated with the rAd-p53 injection.
In conclusion, intrasurgical wound injection of rAd-p53 combined with post-surgery radiotherapy can reduce the locoregional recurrence of TCa and GCa, and improve the OS and DFS.
